Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    bet-at-home

    MCap

    EUR31m

    Last close

    EUR4.35

    ▲ 1.02 (30.63%)

    KEFI Gold and Copper

    MCap

    GBP38m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    OpGen

    MCap

    USD7m

    Last close

    USD0.49

    ▲ 0.05 (11.62%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Mendus (OMX: IMMU)

Last close As at 26/07/2024

SEK8.10

▲ −0.15 (−1.82%)

Market capitalisation

SEK411m

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by pharmaceutical and biotech companies. Investors should expect relatively rich newsflow from this subsector over the next few years.

Latest Insights

View More

Healthcare | Flash note

Mendus — Collaboration unveils path forward for ilixadencel

Healthcare | Flash note

Mendus — Recent clinical data highlight vididencel’s potential

Healthcare | edison tv

Executive interview with Erik Manting PhD, CEO of Mendus

Healthcare | Update

Mendus — All hands on deck as inflection points approach
Mendus_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Alex Karlsson-Parra

    CSO

  • Erik Manting

    CEO

  • Jeroen Rovers

    CMO

  • Leopold Bertea

    CTO

  • Lotta Ferm

    CFO

Balance Sheet

Forecast net cash (SEKm)

68.7

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.6 (2.5) (60.1)
Relative 3.6 (8.7) (66.3)
52 week high/low SEK1.3/SEK0.3

Financials

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatment arms and the trial will involve up to 43 STS patients. The trial is sponsored by Institut Bergonié and Mendus will supply ilixadencel to the STS cohort (regorafenib and avelumab will be supplied by Bayer and Merck KGaA, respectively). Management expects trial preparations for the ilixadencel arm to be completed in H224, with the first patient data expected in H126. We anticipate that trial readouts will influence the clinical path forward.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 3.4 (128.8) (138.8) (69.6) N/A N/A
2023A 29.6 (94.3) (101.6) (22.0) N/A N/A
2024E 3.1 (118.6) (124.6) (13.3) N/A N/A
2025E 0.0 (119.4) (125.7) (12.5) N/A N/A

Research

Flash note

Healthcare

Mendus — Recent clinical data highlight vididencel’s potential

edison tv

Healthcare

Executive interview with Erik Manting PhD, CEO of Mendus

Healthcare

Flash note

Mendus — Collaboration unveils path forward for ilixadencel

Update

Healthcare

Mendus — All hands on deck as inflection points approach

Flash note

Healthcare

Mendus — Gross proceeds of c SEK69m to advance pipeline

Flash note

Healthcare

Mendus — Regulatory green light for CADENCE trial

Flash note

Healthcare

Mendus — Stars align for CADENCE combination trial

Update

Healthcare

Mendus — Potential disruptor to AML maintenance setting
Mendus_resized

Flash note

Healthcare

Mendus — Poised for an active 2024
Mendus_resized

Update

Healthcare

Mendus — Pursuit of a durable response in AML
Mendus_resized

Flash note

Healthcare

Mendus — Phase II combination to progress lead asset
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free